Background {#Sec1}
==========

Fear of cancer recurrence (FCR), the "fear, worry, or concern relating to the possibility that cancer will come back or progress" \[[@CR1], [@CR2]\], is highly prevalent amongst cancer survivors. Although some degree of FCR is normal and adaptive, high levels are associated with reduced quality of life, functional impairment, distress, anxiety, depression, excessive reassurance-seeking and increased healthcare costs \[[@CR3]--[@CR8]\]. It is estimated that around a third (31--38%) of Dutch curatively-treated cancer survivors experience high FCR \[[@CR3], [@CR9]--[@CR11]\]. FCR seems to be a universal concern of cancer survivors rather than a cancer type-specific problem, estimates of FCR did not differ by cancer types \[[@CR12]\]. There is consistent evidence that younger age, presence and severity of physical symptoms, psychological distress, lower quality of life, female gender and lower education are associated with higher FCR \[[@CR3]\].

Four randomised controlled trials (RCTs) of therapist-delivered interventions to help cancer survivors manage FCR have been published to date \[[@CR13]--[@CR16]\]. Although the theoretical foundations, formats and delivery methods of these interventions differ, all available treatments are based on cognitive behaviour therapy (CBT) and some are delivered online via the internet (eHealth) \[[@CR14], [@CR17], [@CR18]\]. Online CBT is a promising and potentially cost-effective treatment modality \[[@CR19]--[@CR21]\], which is at least as effective as face-to-face CBT for many mental disorders \[[@CR22]--[@CR25]\]. Online CBT may reduce waiting lists, travel time and costs \[[@CR26]\], productivity losses \[[@CR20], [@CR26]\], and improve accessibility \[[@CR20]\]. Possible disadvantages of online therapy include a lack of personal interaction, poorer adherence and less engagement \[[@CR19]\]. Blended therapy, in which face-to-face and online therapy are combined, might bridge this gap. The Survivors' Worries of Recurrent Disease (SWORD) study is a blended CBT (bCBT) treatment for high FCR. Immediate post-treatment efficacy has been established in an RCT which compared bCBT with care as usual (CAU) in Dutch cancer survivors with high FCR \[[@CR14]\]. FCR was significantly reduced at 3 months follow-up in participants who received bCBT compared to those who received CAU (Cancer Worry Scale mean difference of − 3.48, 95% CI -4.69 to − 2.28, *p* \< 0.001) with a medium to large effect size (d = 0.76) \[[@CR14]\]. More detailed methodology and results are reported elsewhere \[[@CR14], [@CR27]\]. Efficacy at 6 and 11 months post-treatment has been demonstrated for two other FCR interventions \[[@CR13], [@CR16]\], however efficacy beyond the first year after treatment has received little attention. Only one trial to date has included a follow-up beyond the first year after treatment ended; this study of a therapist-delivered FCR intervention found that treatment was not more effective than CAU in reducing FCR at 15 months \[[@CR15]\]. No previous studies have evaluated the cost-effectiveness of an individual psychological intervention for FCR, however one study has evaluated the cost-effectiveness of two group-based interventions to reduce fear of progression in cancer patients of mixed disease stage \[[@CR28]\]. This study found that group CBT was less costly than supportive-experiential group therapy with a similar reduction of fear of progression \[[@CR28]\].

With increasingly constrained healthcare budgets it is important to ensure that the benefits of an intervention outweigh the costs \[[@CR29]\]. Therefore, this study aimed to evaluate the efficacy and cost-effectiveness of the SWORD intervention at 9 and 15 months follow-up.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

Detailed information concerning study design, recruitment and inclusion/exclusion criteria is published elsewhere \[[@CR27]\]. Between 2014 and 2016, a multicentre prospective two-arm RCT was conducted investigating the efficacy of bCBT in cancer survivors with high FCR (Cancer Worry Scale score ≥ 14). In total, 88 curatively-treated breast (BC), prostate (PC) and colorectal cancer (CRC) survivors who had completed primary medical treatment at least six months and no longer than five years were included. Eligible participants who gave informed consent were randomly assigned to receive either CAU or bCBT. The RCT was approved by an ethical board (CMO Arnhem-Nijmegen), registered in the Dutch National Trial Register (NTR4423) and adheres to CONSORT guidelines.

Intervention and care as usual {#Sec4}
------------------------------

The intervention was delivered as blended care during a 3-month period: five individual one-hour face-to-face sessions (sessions 1, 2, 3, 5, 8) combined with three 15-min e-consultations (chat application, sessions 4, 6, 7) and access to a website. Therapeutic techniques applied in the intervention included psycho-education, cognitive restructuring, and behavioral modification. One face-to-face booster session followed at three months post-therapy. Participants who received CAU had no restrictions regarding the use of other psychosocial support during the study period.

The website was developed in agreement with Dutch privacy laws equal to HIPAA. All communication from and to their servers was encrypted. The hosting network was certified.

Outcome measures {#Sec5}
----------------

Questionnaires were completed before randomization (baseline, T0), and at three months (T1), nine months (T2) and fifteen months (T3) after baseline assessment. The primary outcome measure was FCR, assessed with the Cancer Worry Scale (CWS). The CWS is a reliable and valid questionnaire which measures FCR on an 8-item 4-level scale \[[@CR10]\]. Total scores range between 8 and 32 and a cut-off score of ≤13 versus ≥14 differentiates between low and high FCR \[[@CR10]\]. Secondary outcomes were FCR severity (Fear of Cancer Recurrence Inventory \[FCRI\] severity subscale) \[[@CR30]\], cancer-specific distress (Impact of Events Scale \[IES\]) \[[@CR31], [@CR32]\], distress (Hospital Anxiety and Depression Scale \[HADS\]) \[[@CR33]\], fatigue (Checklist Individual Strength 8R \[CIS-8R\]) \[[@CR34]\], and health-related quality of life (HRQoL; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 \[EORTC QLQ-C30\]) \[[@CR35]\].

Costs and quality-adjusted life years (QALYs) were used as the outcome measures in the cost-effectiveness analyses. The QALY combines quality (weighed by utility scores) and quantity of life (life years gained) in one measure and is the predominant outcome measure used in health economic evaluations to assess value for money of interventions. QALYs enable comparison of cost-effectiveness of different interventions across different disease areas. Each QALY gained is worth a certain maximum monetary value that governmental organizations or insurance companies are willing to pay; also called willingness to pay (WTP) thresholds. To calculate QALYs, utility scores were obtained by using the EuroQol five dimensions three-level questionnaire (EQ-5D-3 L) and by applying the Dutch EQ-5D tariff \[[@CR36], [@CR37]\]. Utility scores are preference-based quality of life values, generally ranging from 0 (death) to 1 (perfect health). These utilities were multiplied by the duration of follow-up (fifteen months) to calculate QALYs.

The economic evaluation was conducted from a societal perspective, and therefore included medical costs (healthcare resource use and medication), non-medical costs (informal care and loss of productivity from paid work) and costs of the bCBT intervention. Both medical- and non-medical resource use were measured by pre-defined self-reported cost diaries collected at T1, T2 and T3. Resource use volumes were valued using standard Dutch reference prices for 2014 if available (Additional file [1](#MOESM1){ref-type="media"}: Appendix 1) \[[@CR29]\]. The economic impact of absence from paid work was calculated using the friction cost method \[[@CR38]\], which was set at 12 weeks in 2014 in the Netherlands \[[@CR29]\]. Intervention program costs included bottom-up calculated costs of psychologist training, supervision and consultations, in addition to costs of website development, updates and user licences divided by a conservative amount of potential annual users in a regional implementation scenario (Additional file [1](#MOESM1){ref-type="media"}: Appendix 2) \[[@CR39], [@CR40]\]. No costs or effects were discounted due to the short study period.

Statistical analysis {#Sec6}
--------------------

For the analysis of the primary outcome of FCR, all secondary outcomes and health-economic outcomes, a modified intention-to-treat (mITT) analysis was performed; in which participants who experienced a recurrence of cancer during the follow-up period were retained in the analysis, but only their scores before recurrence were included in the analysis.

### Clinical outcomes {#Sec7}

Long-term effects of bCBT on primary and secondary outcomes were examined by fitting a linear mixed-effects model for mean CWS follow-up scores. This model included treatment condition, follow-up time (using discrete time points) and their interaction, with an unstructured residual-error covariance matrix specified to account for the within-person correlation on the repeated follow-up measures. Baseline score and primary cancer type were included as covariates. The latter was a stratification variable for randomisation and was also found to be associated with the probability of missing data at T2 and T3. For the primary outcome of FCR, two sensitivity analyses were conducted. In the first sensitivity analysis, participants who reported a recurrence were excluded from the analysis dataset. The second sensitivity analysis was a per protocol analysis of participants who completed the bCBT intervention (intervention arm) and who had full follow-up data on FCR. All analyses for the clinical outcomes were conducted in Stata 14.2.

Clinically significant improvement (CSI) on levels of FCR between baseline and both T2 and T3 follow-up assessments was established by combining statistically reliable improvement (reliable change index \< 1.96) \[[@CR41]\] and a decrease of CWS scores to the normal range (clinically significant change, CWS \< 14) \[[@CR27]\]. Self-rated improvement had occurred if the participant answered 'yes' to 'feeling much better but still experiencing some FCR' or 'no longer experiencing FCR'.

### Health economic outcomes {#Sec8}

Missing total cost and utility score data per measurement were imputed at the aggregated level separately per treatment arm, by using multiple imputation (MI) by chained equations with predictive mean-matching \[[@CR42], [@CR43]\]. Twenty imputed datasets were created and pooled according to Rubin's rules \[[@CR44]\].

First of all, incremental costs and incremental QALYs between the CAU and bCBT strategies were calculated and statistical differences in non-normally distributed costs and QALYs were tested with bootstrapped t-tests \[[@CR45]\]. Non-parametric percentile bootstrapping with 1000 replications was performed to estimate 95% confidence intervals \[[@CR46]\]. In order to weigh incremental costs against incremental QALYs, the incremental cost-effectiveness ratio (ICER) was calculated by dividing total incremental costs by the incremental QALYs to obtain the costs per QALY gained by the intervention \[[@CR39]\]. Due to substantial differences in EQ-5D baseline utility scores between conditions, regression-based adjustment was performed within the net monetary benefit framework, which values both benefits and costs in monetary terms and therefore enables the use of regression methods \[[@CR47]\]. Incremental net monetary benefit (INMB) statistics were estimated for different WTP thresholds. The INMB was calculated by using the following formula: (incremental QALY \* WTP) -- incremental costs. Cost-effectiveness acceptability curves (CEACs) were constructed which display the probability that bCBT would be cost-effective given specific WTP thresholds \[[@CR48]\]. A sensitivity analysis was conducted which used condition-specific utility scores calculated from the EORTC QLQ-C30 instead of utility scores calculated from the EQ-5D-3 L \[[@CR49]\].

Results {#Sec9}
=======

Sample characteristics {#Sec10}
----------------------

In total, 45 participants were randomly assigned to bCBT and 43 to CAU (Fig. [1](#Fig1){ref-type="fig"}). Both conditions were comparable on demographic characteristics and clinical characteristics (Table [1](#Tab1){ref-type="table"}). Nine participants reported a recurrence at some point during follow-up (bCBT: 8, CAU: 1) and one participant receiving CAU reported a new primary cancer. Three of these patients dropped out of the study (bCBT: 2, CAU: 1). Furthermore, 16 participants dropped out of the study during follow-up for various other reasons (bCBT: 5, CAU: 11; Fig. [1](#Fig1){ref-type="fig"}). Having had colorectal cancer (*p* = 0.047) and having comorbid conditions (*p* = 0.044) was significantly associated with dropout at any stage during the study. The number of completers (who completed all CWS questionnaires and, for bCBT, the full intervention) was 23 in the bCBT and 30 in the CAU condition.Fig. 1CONSORT flow diagram showing recruitment and enrolment of 88 participants. Participants who reported a recurrence, but still filled in questionnaires while they had a recurrence (6 additional patients in the bCBT group), are not listed as 'lost to follow up'. Abbreviations: bCBT, blended cognitive behaviour therapy; CAU, care as usual; BC, breast cancer; CRC, colorectal cancer; PC, prostate cancer; CWS, cancer worry scale; EQ-5D, EuroQol five dimensions questionnaireTable 1Demographic and clinical characteristics at baseline of participants by study groupbCBT (*n* = 45)CAU (*n* = 43)Characteristic*n* (%)*n* (%)Age Mean (SD)58.0 (11.3)59.7 (10.0)Gender Male21 (46.7%)20 (46.5%)Education Low (ISCED 0--2)11 (24.4%)18 (41.9%) Middle (ISCED 3--5)19 (42.2%)10 (23.3%) High (ISCED 6--8)15 (33.3%)15 (34.9%)Employment status Paid Employment17 (37.8%)17 (39.5%) Unemployed8 (17.8%)5 (11.6%) Voluntary work4 (8.9%)8 (18.6%) Retired16 (35.6%)14 (32.6%)Primary cancer site Breast18 (40.0%)18 (41.9%) Colorectal12 (26.7%)10 (23.3%) Prostate15 (33.3%)15 (34.9%)Treatment type Surgery18 (40.0%)11 (25.6%) Radiotherapy0 (0.0%)3 (7.0%) Surgery + Radiotherapy9 (20.0%)9 (20.9%) Surgery + Chemotherapy12 (26.7%)9 (20.9%) Surgery + Radiotherapy + Chemotherapy6 (13.3%)11 (25.6%)Time since diagnosis (years) Mean (SD)2.4 (1.5)2.8 (1.3)Time since last treatment (years) Mean (SD)1.9 (1.5)2.1 (1.4)Number of comorbid diseases 019 (42.2%)14 (32.6%) 1--219 (42.2%)22 (51.2%) 3+7 (15.6%)7 (16.3%)Psychological help in the past yes22 (50.0%)26 (60.5%)Abbreviations: *bCBT* blended cognitive behaviour therapy, *CAU* care as usual, *ISCED* International Standard Classification of Education, *SD* standard deviation

Clinical outcomes {#Sec11}
-----------------

Results for the primary and secondary clinical outcomes are presented in Table [2](#Tab2){ref-type="table"}. The decrease in FCR was significantly greater in participants who received bCBT compared with CAU at all follow-up measurements (Additional file [1](#MOESM1){ref-type="media"}: Appendix 3). At T3, the detected mean difference in FCR remained statistically significant (− 1.787, 95% CI -3.251 to − 0.323, *p* = 0.017), although smaller than at T1 (− 3.534, 95% CI -4.764 to − 2.305, *p* = 0.000) and T2 (− 4.104, 95% CI -5.531 to − 2.677, *p* = 0.000). Similar results were found in the per protocol sensitivity analysis. In the sensitivity analysis which excluded participants with recurrences, the reduction in FCR in the bCBT condition was larger at each follow-up measurement than in the primary analysis (Additional file [1](#MOESM1){ref-type="media"}: Appendix 4).Table 2Effect of treatment (modified intention-to-treat) on primary and secondary outcomes (*n* = 88)bCBT (*n* = 45)CAU (*n* = 43)MeanSE/SD\*MeanSE/SD\*Mean difference95% CI*p* valuePrimary outcome FCR (CWS)  T019.6223.73719.5583.744  T1 unadjusted14.8144.57918.4873.986  T1 adjusted14.7430.43218.2770.454−3.534−4.764 to −2.305**0.000**  T2 unadjusted13.7184.47217.8443.836  T2 adjusted13.9160.49318.0200.534−4.104−5.531 to − 2.677**0.000**  T3 unadjusted14.6844.53916.5164.081  T3 adjusted14.7830.50416.5700.549−1.787−3.251 to −0.323**0.017**Secondary outcomes Multidimensional aspects of FCR  Severity (FCRI)   T021.9094.85023.1166.456   T1 unadjusted16.6057.25122.2825.991   T1 adjusted16.9890.75621.3300.788−4.341−6.497 to −2.185**0.000**   T2 unadjusted15.0256.89721.3135.171   T2 adjusted15.9570.68820.4620.742−4.505−6.513 to −2.497**0.000**   T3 unadjusted15.8427.34319.7335.539   T3 adjusted16.5990.80519.0230.879−2.423−4.785 to −0.062**0.044**Distress, depression, anxiety Distress (HADS)  T014.0897.83615.2098.911  T1 unadjusted9.9518.40217.1319.519  T1 adjusted10.7490.73116.0030.763−5.254−7.334 to −3.174**0.000**  T2 unadjusted9.7187.41215.8629.771  T2 adjusted11.1390.80614.8970.898−3.759−6.134 to −1.383**0.002**  T3 unadjusted9.7788.29214.8899.390  T3 adjusted11.4140.96613.2281.082−1.813−4.669 to 1.0430.213 Anxiety (HADS)  T08.1564.1018.3954.914  T1 unadjusted5.3174.2399.4475.012  T1 adjusted5.6390.4378.9510.456−3.312−4.555 to −2.068**0.000**  T2 unadjusted5.3334.1328.8625.585  T2 adjusted6.0300.5288.5490.588−2.519−4.074 to −0.964**0.002**  T3 unadjusted4.9444.0568.3334.844  T3 adjusted5.7510.5707.7340.638−1.984−3.667 to − 0.301**0.021** Depression (HADS)  T05.9334.2186.8144.722  T1 unadjusted4.6344.5987.6845.152  T1 adjusted5.0500.4247.1310.442−2.081−3.286 to −0.876**0.001**  T2 unadjusted4.3854.0177.0004.751  T2 adjusted5.0420.4186.4060.467−1.363−2.597 to −0.130**0.030**  T3 unadjusted4.8334.6756.5564.956  T3 adjusted5.5820.5045.6110.565−.029−1.520 to 1.4620.970 Cancer-specific distress (IES)  T023.04414.55524.90215.604  T1 unadjusted14.73214.99826.02617.747  T1 adjusted15.5392.06424.5982.208−9.059−15.003 to −3.115**0.003**  T2 unadjusted9.97313.71016.64315.905  T2 adjusted11.1272.08517.1072.391−5.979−12.215 to 0.2560.060  T3 unadjusted14.94414.63318.25915.294  T3 adjusted15.7812.14717.2542.450−1.473−7.883 to 4.9380.653 Fatigue (CIS-8R)  T030.22212.95136.11612.585  T1 unadjusted25.25011.53536.68413.001  T1 adjusted27.9611.13733.4781.176−5.516−8.771 to −2.262**0.001**  T2 unadjusted26.76911.85532.58612.290  T2 adjusted28.6941.29730.5121.444−1.818−5.658 to 2.0220.353  T3 unadjusted26.80611.43630.55613.042  T3 adjusted29.3871.35026.8881.5142.499−1.522 to 6.5210.223Quality of life (EORTC QLQ-C30) Global quality of life  T062.22219.67261.43420.252  T1 unadjusted73.06219.40257.47920.483  T1 adjusted72.5042.55658.0752.68214.4297.153 to 21.705**0.000**  T2 unadjusted72.08321.22962.50021.792  T2 adjusted71.9183.00462.6323.2649.2860.576 to 17.997**0.037**  T3 unadjusted73.02619.60965.27819.948  T3 adjusted72.6722.82367.7423.1084.930−3.331 to 13.1920.242 Physical functioning  T087.70413.40683.95316.269  T1 unadjusted89.38011.73580.85520.010  T1 adjusted87.5521.52782.8861.6064.666.296 to 9.037**0.036**  T2 unadjusted88.75015.14886.45814.809  T2 adjusted86.2461.73787.7661.893−1.519−6.583 to 3.5450.557  T3 unadjusted89.64913.92484.30114.560  T3 adjusted87.9861.59286.8291.7211.156−3.479 to 5.7920.625 Role functioning  T077.03726.18174.80625.295  T1 unadjusted85.65921.07674.12323.474  T1 adjusted84.5432.96375.5473.1428.9960.503 to 17.489**0.038**  T2 unadjusted83.75023.41582.29221.972  T2 adjusted82.7663.40782.7053.7420.061−9.887 to 10.0080.991  T3 unadjusted89.03517.01384.40923.148  T3 adjusted87.3882.77785.3573.0432.031−6.095 to 10.1570.624 Emotional functioning  T064.81522.88366.86022.456  T1 unadjusted81.58923.18560.25629.830  T1 adjusted81.6472.93459.9783.07821.66913.326 to 30.011**0.000**  T2 unadjusted80.20822.46361.71928.544  T2 adjusted78.9593.25960.7853.54018.1748.731 to 27.617**0.000**  T3 unadjusted77.85123.59268.54825.973  T3 adjusted77.5072.98768.6683.2428.8390.179 to 17.499**0.046** Cognitive functioning  T072.96324.69268.99225.350  T1 unadjusted80.62019.89762.39328.541  T1 adjusted79.9772.92064.6623.07115.3156.989 to 23.641**0.000**  T2 unadjusted82.50019.95472.91728.945  T2 adjusted80.1303.27674.9903.5935.140−4.421 to 14.7010.292  T3 unadjusted79.38622.73868.28025.587  T3 adjusted76.9943.17171.7803.4425.214−4.013 to 14.4410.268 Social functioning  T080.00023.19271.31824.754  T1 unadjusted89.92217.49576.92326.384  T1 adjusted87.8682.90779.2253.0558.6430.306 to 16.979**0.042**  T2 unadjusted85.83322.50480.20822.175  T2 adjusted83.3023.05281.1273.3102.176−6.727 to 11.0780.632  T3 unadjusted88.15819.72386.02219.292  T3 adjusted85.9242.55689.0592.7593.135−10.641 to 4.3700.413NOTE. Linear mixed-effects models were used to calculate all *p*-values. Adjusted means were adjusted for the baseline covariates primary cancer site and baseline value of the corresponding outcome; unadjusted means were unadjusted for covariates. Boldface type indicates a statistically significant effect for adjusted means (*p* \< 0.05)\*SEs are reported for adjusted means, SDs for unadjusted meansAbbreviations: *bCBT* blended cognitive behaviour therapy, *CAU* care as usual; *FCR* fear of cancer recurrence, *CWS* Cancer Worry Scale, *FCRI* Fear of Cancer Recurrence Inventory, *HADS* Hospital Anxiety and Depression Scale, *IES* Impact of Events Scale, *CIS-8R* Checklist Individual Strength 8R, *EORTC QLQ-C30* European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, *SD* standard deviation, *SE* standard error

Regarding the secondary outcomes, participants receiving bCBT experienced significantly greater improvement at each follow-up measurement on anxiety, emotional functioning and the FCRI severity subscale compared with CAU. Significant improvement at T1 and T2 was found on distress, depression and global quality of life. On the other six secondary outcomes (cancer-specific distress, fatigue and physical, role, social and cognitive functioning), a statistically significant effect was found at T1.

Significantly more participants receiving bCBT compared with CAU reported reliable improvement (78% vs. 19%, *p* ≤ 0.001), clinically significant change (58% vs. 9%, *p* ≤ 0.001), clinically significant improvement (51% vs. 3%, *p* ≤ 0.001) and self-rated improvement (74% vs. 41%, *p* = 0.007) at T2. At T3, only clinically significant change (50% vs. 16%, *p* = 0.038) and self-rated improvement (72% vs. 40%, *p* = 0.020) remained significantly higher in bCBT (Additional file [1](#MOESM1){ref-type="media"}: Appendix 5).

Health economic outcomes {#Sec12}
------------------------

Participants receiving bCBT reported substantially lower costs on most medical resource categories, including medical specialists, psychosocial help and diagnostics (Additional file [1](#MOESM1){ref-type="media"}: Appendix 6). Costs of the bCBT intervention programme amounted to €466 (Additional file [1](#MOESM1){ref-type="media"}: Appendix 2), which were added to the costs made by bCBT participants. Total costs (combined medical, non-medical and bCBT intervention costs) over the complete follow-up period were non-significantly lower in those who received bCBT compared with CAU (− €164, 95% CI -2018 to 2502, *p* = 0.891).

Results of the different cost-effectiveness analyses are shown in Table [3](#Tab3){ref-type="table"}. Baseline EQ-5D utility scores were substantially higher in the bCBT condition (0.78 \[SD = 0.18\]) than in CAU (0.68 \[SD = 0.22\]) (Additional file [1](#MOESM1){ref-type="media"}: Appendix 3). Mean QALYs unadjusted for this baseline difference were significantly higher in the bCBT condition (1.027 compared to 0.913, *p* = 0.018). However, QALYs were non-significantly different when these were adjusted for baseline EQ-5D utility scores (0.984 compared to 0.957, *p* = 0.385) and when QALYs were calculated from QLQ-C30 utility scores (1.107 compared to 1.074, *p* = 0.137).Table 3Results of the different cost-effectiveness analysesUnadjustedAdjustedQLQ-C30bCBTCAUbCBTCAUbCBTCAUCostsMean60016165600161656001616595% CI4552 to 76644657 to 78504552 to 76644657 to 78504552 to 76644657 to 7850Incremental costsMean−164−164−16495% CI−2018 to 2502−2018 to 2502−2018 to 2502QALYsMean1.0270.9130.9840.9571.1071.07495% CI0.966 to 1.0830.839 to 0.9800.941 to 1.0280.912 to 1.0011.074 to 1.1351.046 to 1.100Incremental QALYsMean0.1140.0280.03395% CI0.026 to 0.206\*−0.031 to 0.090−0.012 to 0.072ICER€-1081 / QALY€2049 / QALY€-6189 / QALYINMB at WTP of 0Mean€164€-57€16495% CI€-2018 to €2502€-2709 to €2370€-2081 to 2419INMB at WTP of €20,000Mean€2403€498€80795% CI€-893 to €5454€-2514 to €3269€-1898 to €3249INMB at WTP of €50,000Mean€5761€1331€177095% CI€386 to €11,274\*€-3189 to €5773€-1322 to €5064NOTE. Unadjusted and adjusted cost-effectiveness analyses used QALYs calculated from EQ-5D utilities, while the QLQ-C30 analysis used QALYs calculated from EORTC QLQ-C30 utilities. Estimates in the adjusted cost-effectiveness analysis were adjusted for baseline EQ-5D utility scores. Confidence intervals were obtained after bootstrapping with 1000 replicationsAbbreviations: *bCBT* blended cognitive behaviour therapy, *CAU* care as usual, *QLQ-C30* European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, *ICER* incremental cost-effectiveness ratio, *INMB* incremental net monetary benefit, *WTP* willingness to pay, *QALY* quality adjusted life-year\*Significant difference between the two conditions (*p* \< 0.05)

Since the total costs were lower and total QALYs were higher when QALYs were unadjusted for baseline utility differences, bCBT was the dominant strategy (negative ICER) in this analysis. The same applies to the analysis which used QALYs calculated from QLQ-C30 utility scores instead of EQ-5D utility scores. An ICER of €2049 per QALY gained was found when QALYs were adjusted for baseline EQ-5D utility differences, since bCBT was both less costly and less effective in this analysis. INMBs in the unadjusted and QLQ-C30 analyses were in favour of the bCBT condition regardless of society's WTP per QALY gained, while adjusted INMBs were in favour of bCBT above a WTP of €2049 per QALY gained (which is equal to the ICER). However, all INMBs had wide confidence intervals, most of which included 0 at all WTP values. The CEAC shows that there is a 48 to 56% probability that bCBT is cost-saving compared to CAU, and a 62 to 95% probability that bCBT is more cost-effective than CAU at a WTP of €20,000 (Fig. [2](#Fig2){ref-type="fig"}). This probability obviously increases as WTP values increase.Fig. 2Cost-effectiveness acceptability curves of the different cost-effectiveness analyses, showing the probability that the intervention is cost-effective at different willingness to pay (WTP) thresholds. Abbreviations: bCBT, blended cognitive behaviour therapy; QALY, quality-adjusted life year; QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30

Discussion {#Sec13}
==========

This study investigated the long-term efficacy and cost-effectiveness of bCBT to reduce FCR in PC, BC and CRC survivors with high FCR. It was shown previously that bCBT resulted in a statistically and clinically significant reduction of FCR severity immediately post-treatment (3 months) compared with CAU \[[@CR14]\]. The current study found that the effect of bCBT remained significant during follow-up at 9 and 15 months \[[@CR50]\]. Findings were confirmed in the sensitivity analyses. Furthermore, more bCBT than CAU participants reported self-rated improvement and clinically significant improvement at 9 and 15 months. However, the difference in clinically significant improvement at T3 was not statistically significant, reflecting the finding that FCR increased slightly in the bCBT condition and significantly decreased in the CAU condition between 9 and 15 months from baseline. The decrease in FCR over time in the CAU condition is inconsistent with previous literature reviews stating that high FCR remains stable over time without intervention \[[@CR3], [@CR5], [@CR51], [@CR52]\]. However, CAU participants received considerably more additional psychosocial support (by either a psychologist, mental health nurse, social worker or psychiatrist) than bCBT participants which may explain this decrease. For secondary outcomes, those receiving bCBT improved significantly on multidimensional aspects of FCR, anxiety and emotional functioning at each follow-up measurement. Other secondary outcomes (distress, depression, global quality of life) improved at T1 and T2, while the remainder (cancer-specific distress, fatigue and physical, role, social and cognitive functioning) only improved at 3 months follow-up.

In the economic evaluation, total costs were found to be numerically but not significantly lower in the bCBT condition. Intervention costs were relatively low when calculated for a conservative annual number of potential users. The amount of additional QALYs was small and not statistically significant when adjusted for baseline EQ-5D utility scores and in the sensitivity analysis using QLQ-C30 utility scores. All cost-effectiveness analyses resulted in low costs of bCBT per QALY gained and relatively high probabilities that bCBT is cost-saving compared to CAU. The maximum WTP for an additional QALY in the Netherlands is dependent on the burden of disease of the addressed condition, ranging from €20,000 to €80,000 \[[@CR53]\]. As the disease burden of high FCR is not yet reported, we decided to use the most conservative WTP of €20,000; at which the probability that bCBT is cost effective ranged from 62 to 95%. However, since total costs and QALYs were not significantly different and the INMBs had relatively wide confidence intervals which included zero, it cannot be concluded that bCBT is more cost-effective than CAU. Instead, it could be concluded that bCBT and CAU are similar in terms of costs and QALYs. Nonetheless, as costs of eHealth interventions are partly dependant on the number of users \[[@CR54]\], it is envisaged that when implemented in routine care, the intervention will probably become more cost-effective than demonstrated here.

Like other recent RCTs of psychological interventions, the present study has demonstrated immediate and medium-term benefits of a CBT-based psychological intervention for FCR. However, to our knowledge, this is the first study to demonstrate efficacy and cost-effectiveness of a psychological intervention for FCR beyond the first year after treatment. Several on-going trials of interventions for FCR include cost-effectiveness outcomes, and it will be interesting to compare health-economic results \[[@CR55]--[@CR57]\].

Methodological strengths of this study include the rigorous RCT design and the broad range of different clinical and health economic outcomes. Both statistical and clinical change was evaluated, and findings were adjusted for covariates and confirmed by sensitivity analyses. Despite being adequately powered, a relatively high number of dropouts (18%) and participants with recurrence (11%) was observed during follow-up. Recurrences were self-reported by participants and not systematically investigated in medical records for privacy reasons. More participants in the bCBT than in the CAU condition reported a recurrence, which may have occurred due to higher follow-up adherence of the intervention group. It is noteworthy that a number of participants with recurrence still completed follow-up questionnaires; however, their data after recurrence was excluded from the main analysis since we were only interested in the efficacy and cost-effectiveness of bCBT in disease-free cancer survivors. Although it is possible that the intervention remains suitable for people with recurrent disease, the extent to which bCBT translates to or requires adaptation for patients with advanced disease remains a question for future research.

A further limitation is that this study was not powered to detect differences in cost-effectiveness and therefore these outcomes should be interpreted with caution. Self-reported cost diaries are considered to be feasible and valid for collecting cost data \[[@CR58]\], although in the current study it was not possible to distinguish between routine follow-up consultations and consultations due to reassurance-seeking behaviour related to FCR, which may have influenced results. Furthermore, baseline cost data, inability to perform unpaid work, limited job performance while at work and travel costs were not measured.

Baseline differences on EQ-5D utility scores were substantial while all other baseline characteristics were comparable between conditions. These differences are likely to have occurred by chance, as randomisation was performed independently by a computer-generated allocation sequence in the RCT. However, the EQ-5D has been previously reported to be less sensitive to changes in psychological well-being due to dominance of physical health domains \[[@CR59]\]. It is possible that the psychological well-being item in the EQ-5D ('anxiety/depression') may not be sensitive to the psychological impact of FCR, as cancer survivors may see FCR as a normal or rational fear and not consider themselves to be anxious or depressed. Indeed, a relatively large proportion of participants in both conditions (33% in CAU and 47% in bCBT) reported no problems with anxiety or depression at baseline, even though all had high FCR at inclusion. Therefore, we additionally used the EORTC QLQ-C30 to calculate QALYs, which may be more sensitive than the EQ-5D in this population. This analysis resulted in higher mean QALY values (as expected) \[[@CR49]\], but incremental QALYs were comparable to findings in the adjusted EQ-5D analysis; indicating that those results are robust.

Conclusions {#Sec14}
===========

This study demonstrates that bCBT is statistically and clinically more effective than CAU over the first 15 months post-treatment, and a relatively inexpensive intervention with similar costs and QALYs as CAU. However, results should be replicated in larger samples and in subgroups of the investigated population.
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Additional file 1:**Appendix 1.** Reference prices per healthcare resource category. A list of all healthcare resources measured by the cost diaries in this study and the associated unit cost per resource, which were used to calculate costs per study participant. **Appendix 2.** Calculation of bCBT intervention programme costs. A description of how bCBT intervention costs were calculated bottom-up; which were subsequently used in the cost-effectiveness analyses for the bCBT group. **Appendix 3.** Figures of mean CWS scores, mean EQ-5D utility scores and mean EORTC QLQ-C30 utility scores over time by study group. Visual representation of mean CWS scores, EQ-5D utility scores (unadjusted) and EORTC QLQ-C30 utility scores at each follow-up measurement (3, 9, 15 months). **Appendix 4.** Sensitivity analyses results conducted on the primary CWS outcome. Results of the sensitivity analysis which excluded participants who reported a recurrence and the per protocol sensitivity analysis, which only included participants who completed the intervention and who had full follow-up FCR data. **Appendix 5.** Reliable improvement, clinically significant change, clinically significant improvement and self-rated improvement in FCR severity. Results of analyses which investigated the clinical relevance of FCR improvement at 9 months and 15 months follow-up by treatment group for complete cases. Results of clinical relevancy analyses at 3 months follow-up are published elsewhere \[[@CR15]\]. **Appendix 6.** Costs per assessment per resource category. Table of mean costs measured per resource category per follow-up assessment per study group. Costs per resource category are listed only for complete cases, since missing cost data were imputed at the aggregated (total cost) level. (DOCX 176 kb)
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:   Curatively-treated colorectal cancer survivor
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RCT

:   Randomised controlled trial
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